Axe Compute (NASDAQ:AGPU – Get Free Report) and ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
Profitability
This table compares Axe Compute and ChronoScale Corporation Common Stock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Axe Compute | -470,383.31% | -7,363.67% | -626.32% |
| ChronoScale Corporation Common Stock | -135.66% | -197.81% | -74.17% |
Volatility & Risk
Axe Compute has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500. Comparatively, ChronoScale Corporation Common Stock has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Insider & Institutional Ownership
Analyst Recommendations
This is a summary of current ratings and target prices for Axe Compute and ChronoScale Corporation Common Stock, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Axe Compute | 1 | 0 | 0 | 0 | 1.00 |
| ChronoScale Corporation Common Stock | 1 | 1 | 0 | 0 | 1.50 |
ChronoScale Corporation Common Stock has a consensus price target of $6.00, suggesting a potential downside of 71.33%. Given ChronoScale Corporation Common Stock’s stronger consensus rating and higher possible upside, analysts clearly believe ChronoScale Corporation Common Stock is more favorable than Axe Compute.
Earnings & Valuation
This table compares Axe Compute and ChronoScale Corporation Common Stock”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Axe Compute | $120,000.00 | 791.85 | -$233.10 million | ($8.18) | -1.01 |
| ChronoScale Corporation Common Stock | $12.80 million | 5.82 | -$11.69 million | ($5.38) | -3.89 |
ChronoScale Corporation Common Stock has higher revenue and earnings than Axe Compute. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than Axe Compute, indicating that it is currently the more affordable of the two stocks.
Summary
ChronoScale Corporation Common Stock beats Axe Compute on 9 of the 13 factors compared between the two stocks.
About Axe Compute
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
About ChronoScale Corporation Common Stock
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Receive News & Ratings for Axe Compute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axe Compute and related companies with MarketBeat.com's FREE daily email newsletter.
